secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001728117-24-000093
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio Q3 net loss $30.8M; cash $327M, runway into H1 2027
----------------------------------------------------------------

- Net loss of $30.8M ($0.14/share) vs $40.0M ($0.21/share) in Q3 2023; revenue from Chiesi collaboration was $9.5M.
- Cash, cash equivalents & marketable securities $327M as of Sept 30, 2024; expected to fund operations into H1 2027.
- Phase 3 PROSERA trial in PAH enrollment ongoing; topline results expected Q4 2025.
- Expect to commence global registrational Phase 3 trial for PH-ILD in mid-2025.
- R&D expenses $34.9M (up from $31.2M); G&A $8.5M (down from $9.3M) YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811724000093/0001728117-24-000093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811724000093/goss-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001728117-24-000093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer